On 20 July 2026, Zhaoke Ophthalmology announced that its fixed-dose, once-daily eye-drop YUVEZZI™ (carbachol 2.75% + brimonidine tartrate 0.1%) obtained marketing approval from the Pharmaceutical Administration Bureau of the Macau SAR on 13 July 2026 for the treatment of presbyopia.

YUVEZZI™ is a preservative-free, room-temperature formulation that constricts the pupil to create a pinhole effect, enhancing near and intermediate vision for adults typically over 45 years old. The product was in-licensed from U.S. partner Tenpoint Therapeutics, which received U.S. FDA approval for the same indication in January 2026.

Prior to the Macau nod, the therapy was cleared in June 2026 by the Hainan Provincial Medical Products Administration for clinical use at Boao Super Hospital as a clinically urgent imported drug.

Zhaoke Ophthalmology is actively pursuing inclusion of YUVEZZI™ in the “Hong Kong-Macau Medicine and Equipment Connect” programme. If approved, this route would allow designated medical institutions in mainland cities within the Greater Bay Area to access the drug once it has been procured by public hospitals in Hong Kong or Macau.

The company cautioned that successful development and full commercialisation of YUVEZZI™ are not guaranteed and advised shareholders and potential investors to exercise prudence when dealing in its shares.